Common Use
Wynzora (calcipotriene 0.005% and betamethasone dipropionate 0.064%) is a prescription topical cream indicated for the treatment of plaque psoriasis in adult patients. This innovative combination cream unites two complementary therapeutic agents in a single, easy-to-apply formulation: calcipotriene, a synthetic vitamin D3 analog that normalizes abnormally accelerated skin cell growth (keratinocyte proliferation) and promotes healthy skin cell differentiation, and betamethasone dipropionate, a potent corticosteroid that rapidly suppresses the inflammatory immune response, reducing redness, itching, and scaling. Together, these dual mechanisms address both the underlying pathology and the visible symptoms of plaque psoriasis more effectively than either component alone. Wynzora cream helps reduce plaque thickness, erythema (redness), scaling, and the persistent itching that significantly impacts daily life and sleep quality. Its cream vehicle is specifically designed for improved cosmetic acceptability and patient adherence compared to traditional ointment-based psoriasis treatments. If you want to buy Wynzora online, this advanced combination psoriasis cream offers clinically proven efficacy with superior patient comfort and convenience.

Dosage and Direction
Apply a thin layer of Wynzora cream to the affected psoriatic plaques once daily, preferably in the evening or at bedtime. Gently rub the cream into the skin until it is fully absorbed. Wash your hands thoroughly after each application unless the hands themselves are being treated. Treatment duration should generally not exceed 8 weeks of continuous use without medical reassessment, as prolonged corticosteroid use may lead to skin-related adverse effects. Do not exceed the maximum recommended weekly application amount as directed by your dermatologist — typically no more than 100 grams per week. Do not apply Wynzora to more than 30% of total body surface area. Follow your doctor's specific instructions regarding treatment areas and duration.

Precautions
Before using Wynzora, inform your doctor if you have calcium metabolism disorders (hypercalcemia, hypercalciuria), kidney disease, a history of skin infections (bacterial, viral, or fungal), skin atrophy, or a history of adverse reactions to corticosteroids. Avoid applying Wynzora to the face, groin, axillae (underarms), or intertriginous areas (skin folds) unless specifically directed by your dermatologist, as these thin-skinned areas are particularly susceptible to corticosteroid-related side effects such as skin thinning and striae. Do not use the cream under occlusive dressings unless prescribed, as occlusion significantly increases systemic corticosteroid absorption. Monitor calcium levels if large body surface areas are treated or treatment is prolonged. Wynzora may cause photosensitivity — use sun protection on treated areas.

Contraindications
Wynzora is contraindicated in patients with known hypersensitivity or allergy to calcipotriene, betamethasone dipropionate, or any inactive ingredient in the cream formulation. Do not use on psoriasis lesions complicated by untreated bacterial, viral (including herpes simplex, varicella), or fungal skin infections, as the immunosuppressive action of the corticosteroid component may worsen infections. Wynzora is also contraindicated in patients with erythrodermic, exfoliative, or pustular psoriasis variants, and in facial psoriasis without specific medical guidance. It is not approved for use in pediatric patients.

Possible Side Effects
Common side effects of Wynzora include mild to moderate skin irritation at the application site, including itching (pruritus), burning or stinging sensation, redness (erythema), folliculitis, and skin peeling. These local reactions are usually transient and diminish with continued use. With prolonged or extensive use, corticosteroid-related effects may develop, including skin thinning (atrophy), stretch marks (striae), telangiectasia (visible small blood vessels), easy bruising, perioral dermatitis, or acneiform eruptions. Systemic effects — such as hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome features, or elevated blood calcium levels from calcipotriene absorption — are rare but possible with extensive use. Contact your dermatologist if you notice skin thinning, persistent irritation, or signs of infection in treated areas.

Drug Interaction
Clinically significant systemic drug interactions with Wynzora are unlikely due to its topical administration and limited systemic absorption under normal use conditions. However, avoid concurrent application of other topical corticosteroids, topical vitamin D analogs, or potentially irritating topical products on the same treated areas unless specifically advised by your dermatologist, as combinations may increase the risk of skin irritation or excessive corticosteroid absorption. If you are taking oral corticosteroids or medications affecting calcium metabolism, inform your doctor, as calcipotriene may potentially contribute to elevated calcium levels. Provide your healthcare provider with a complete list of all medications you are using.

Missed Dose
If you miss your daily application of Wynzora, apply it as soon as you remember on the same day. If it is already close to the next scheduled application time, skip the missed dose and resume your regular once-daily schedule the following day. Do not apply extra cream or a double layer to make up for a missed application, as excessive use increases the risk of side effects.

Overdose
Excessive or prolonged topical application of Wynzora may increase the risk of corticosteroid-related systemic side effects (HPA axis suppression, Cushing's syndrome symptoms) or elevated blood calcium levels (hypercalcemia) from calcipotriene absorption. If excessive amounts have been applied or symptoms of systemic toxicity develop, discontinue use and seek medical evaluation. Treatment is supportive and symptom-based, with monitoring of serum calcium and adrenal function.

Storage
Store Wynzora cream at controlled room temperature between 20°C and 25°C (68°F to 77°F), away from heat, freezing temperatures, and direct sunlight. Keep the tube tightly closed when not in use. Store out of reach of children. Do not use after the expiration date printed on the tube or outer packaging.

Disclaimer

We provide only general information about medications which does not cover all directions, possible drug integrations, or precautions. Information at the site cannot be used for self-treatment and self-diagnosis. Any specific instructions for a particular patient should be agreed with your health care adviser or doctor in charge of the case. We disclaim reliability of this information and mistakes it could contain. We are not responsible for any direct, indirect, special or other indirect damage as a result of any use of the information on this site and also for consequences of self-treatment.